Cargando…

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results

OBJECTIVES: To evaluate 6-month effectiveness of ustekinumab versus tumour necrosis factor inhibitor (TNFi), analysing predictors of low disease activity (LDA)/remission. METHODS: PsABio is a prospective, observational cohort study of patients with psoriatic arthritis (PsA) at 92 sites in eight Euro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smolen, Josef S, Siebert, Stefan, Korotaeva, Tatiana V, Selmi, Carlo, Bergmans, Paul, Gremese, Elisa, Joven-Ibáñez, Beatriz, Katsifis, Gkikas, Noël, Wim, Nurmohamed, Michael T, Richette, Pascal, Sfikakis, Petros P, de Vlam, Kurt, Theander, Elke, Gossec, Laure
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Psoriatic Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522461/ https://www.ncbi.nlm.nih.gov/pubmed/34162594 http://dx.doi.org/10.1136/annrheumdis-2021-220263

Ejemplares similares

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study
por: Gossec, Laure, et al.
Publicado: (2022)

Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022)

Ustekinumab Treatment and Improvement of Physical Function and Health‐Related Quality of Life in Patients With Psoriatic Arthritis
por: Rahman, Proton, et al.
Publicado: (2016)

Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study
por: Tillett, William, et al.
Publicado: (2023)

Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data
por: Van Kuijk, Arno W R, et al.
Publicado: (2023)

Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
por: Richette, Pascal, et al.
Publicado: (2023)

Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries
por: Lucasson, Florian, et al.
Publicado: (2022)

Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce
por: De Marco, Gabriele, et al.
Publicado: (2023)

Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
por: McInnes, Iain B, et al.
Publicado: (2019)

Orthopaedic interventions in patients with psoriatic arthritis: a descriptive report from the SPAR cohort
por: Haque, Naba, et al.
Publicado: (2016)

Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments
por: Vandendorpe, Ann-Sophie, et al.
Publicado: (2019)

Systematic review of the use of CRP in clinical trials for psoriatic arthritis: a concern for clinical practice?
por: Houttekiet, Charlotte, et al.
Publicado: (2022)

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial
por: Kavanaugh, Arthur, et al.
Publicado: (2015)

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
por: Helliwell, Philip S, et al.
Publicado: (2020)

Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise – a review
por: Lubrano, Ennio, et al.
Publicado: (2023)

Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study
por: Leung, Ying Ying, et al.
Publicado: (2023)

Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
por: Ostor, Andrew J K, et al.
Publicado: (2022)

Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis
por: Borst, Carina, et al.
Publicado: (2021)

Extent of axial damage in psoriatic arthritis and spondyloarthritis: comparative data from the BEPAS and (Be-)GIANT multicentre cohorts
por: de Hooge, Manouk, et al.
Publicado: (2023)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
por: de Vlam, Kurt, et al.
Publicado: (2021)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2022)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
por: Strand, Vibeke, et al.
Publicado: (2019)

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2021)

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study
por: Coates, Laura C., et al.
Publicado: (2022)

Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies
por: Gladman, Dafna D., et al.
Publicado: (2019)

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
por: van der Heijde, Désirée, et al.
Publicado: (2016)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
por: Ritchlin, Christopher T, et al.
Publicado: (2023)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
por: Mease, Philip J, et al.
Publicado: (2020)

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
por: Coates, Laura C, et al.
Publicado: (2023)

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
por: Smolen, Josef S, et al.
Publicado: (2020)

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
por: Sweet, Kristen, et al.
Publicado: (2021)

Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti–tumor necrosis factor therapies
por: Saad, Amr A, et al.
Publicado: (2010)

Investigation of association of the IL12B and IL23R genes with psoriatic arthritis
por: Filer, Charlotte, et al.
Publicado: (2008)

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study
por: Gladman, D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nqo11vbl12r0bjfbgmh10kanc0